Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib

被引：23
|
作者：
Mayer, K. [1 ]
Gielen, G. H. [2 ]
Willinek, W. [3 ]
Muller, M. C.
Wolf, D. [1 ]
机构：
[1] Univ Hosp Bonn, Med Clin 3 Oncol Haematol & Rheumatol, Bonn, Germany
[2] Univ Hosp Bonn, Inst Neuropathol, Bonn, Germany
[3] Univ Hosp Mannheim, Med Clin 3, Mannheim, Germany
来源：
LEUKEMIA | 2014年 / 28卷 / 04期
关键词：
CHRONIC MYELOID-LEUKEMIA; ARTERIAL OCCLUSIVE DISEASE; NILOTINIB THERAPY; VASCULAR EVENTS; IMATINIB;
D O I：
10.1038/leu.2013.320
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：976 / 977
页数：2
相关论文
共 50 条
  • [1] Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib
    K Mayer
    G H Gielen
    W Willinek
    M C Müller
    D Wolf
    [J]. Leukemia, 2014, 28 : 976 - 977
  • [2] EVALUATION OF THE EFFECT AND SAFETY OF PONATINIB AS THIRD-LINE TREATMENT FOR PATIENTS WITH CHRONIC MYELOID LEUKAEMIA IN CHRONIC PHASE
    Patir, P.
    Uysal, A.
    Duran, M.
    Soyer, N.
    Vural, F.
    Saydam, G.
    [J]. LEUKEMIA RESEARCH, 2016, 49 : S28 - S28
  • [3] A MODEL-BASED ASSESSMENT OF THE BENEFITS AND RISKS OF PONATINIB VERSUS BOSUTINIB IN THIRD-LINE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
    Cartier, S.
    Parthan, A.
    McGarry, L.
    Weinstein, M.
    [J]. HAEMATOLOGICA, 2015, 100 : 149 - 150
  • [4] Case Presentations: Allograft or Third-Line Therapy in Very Resistant CML
    Radich, Jerald P.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S32 - S33
  • [5] Efficacy and safety of nilotinib as third-line therapy in an elderly patient with CML
    Caocci, Giovanni
    Atzeni, Sandra
    La Nasa, Giorgio
    [J]. CLINICAL MANAGEMENT ISSUES, 2012, 6 : 15 - 18
  • [6] Evaluation of Efficacy and Safety of Ponatinib as Third-line Treatment in Patients with the Diagnosis of Chronic Phase Chronic Myeloid Leukemia
    Patir, Pusem
    Soyer, Nur
    Vural, Filiz
    Saydam, Guray
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2016, 26 (04): : 224 - 226
  • [7] MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) ANALYSIS FOR PONATINIB VS BOSUTINIB IN THIRD-LINE CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
    Iannazzo, S.
    McGarry, L.
    Lustgarten, S.
    Chiroli, S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A577 - A577
  • [8] Targeting FGF for third-line treatment of mRCC
    Sarah Payton
    [J]. Nature Reviews Urology, 2014, 11 (4) : 186 - 186
  • [9] Treatment of epilepsy with third-line antiepileptic drugs
    Chahem, J.
    Bauer, J.
    [J]. NERVENARZT, 2007, 78 (12): : 1407 - 1412
  • [10] Third-Line Treatment Options for Kidney Cancer
    Posadas, Edwin M.
    Limvorasak, Suwicha
    Figlin, Robert A.
    [J]. ONCOLOGY-NEW YORK, 2016, 30 (09): : 813 - +
12345